ULTI Stock Overview
A biotech company, develops immunotherapies against cancers in Norway. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Ultimovacs ASA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NOK 2.55 |
| 52 Week High | NOK 165.00 |
| 52 Week Low | NOK 1.57 |
| Beta | 0.92 |
| 1 Month Change | 18.06% |
| 3 Month Change | 34.21% |
| 1 Year Change | -97.85% |
| 3 Year Change | -97.63% |
| 5 Year Change | -93.38% |
| Change since IPO | -91.77% |
Recent News & Updates
Recent updates
Companies Like Ultimovacs (OB:ULTI) Can Afford To Invest In Growth
Feb 21
Ultimovacs (OB:ULTI) Is In A Strong Position To Grow Its Business
Oct 26Companies Like Ultimovacs (OB:ULTI) Are In A Position To Invest In Growth
Oct 05Ultimovacs (OB:ULTI) Is In A Good Position To Deliver On Growth Plans
May 19Here's Why We're Not At All Concerned With Ultimovacs' (OB:ULTI) Cash Burn Situation
Jul 27Shareholder Returns
| ULTI | NO Biotechs | NO Market | |
|---|---|---|---|
| 7D | 0.2% | -3.9% | -2.8% |
| 1Y | -97.8% | -73.8% | -0.8% |
Return vs Industry: ULTI underperformed the Norwegian Biotechs industry which returned -73.8% over the past year.
Return vs Market: ULTI underperformed the Norwegian Market which returned -0.8% over the past year.
Price Volatility
| ULTI volatility | |
|---|---|
| ULTI Average Weekly Movement | 13.9% |
| Biotechs Industry Average Movement | 14.0% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in NO Market | 10.9% |
| 10% least volatile stocks in NO Market | 2.6% |
Stable Share Price: ULTI's share price has been volatile over the past 3 months compared to the Norwegian market.
Volatility Over Time: ULTI's weekly volatility has decreased from 20% to 14% over the past year, but is still higher than 75% of Norwegian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 17 | Carlos de Sousa | www.ultimovacs.com |
Ultimovacs ASA, a biotech company, develops immunotherapies against cancers in Norway. Its lead product candidate is UV1, a peptide-based therapeutic cancer vaccine that induces a specific T cell response against the pan-tumor antigen telomerase. Ultimovacs ASA was incorporated in 2011 and is headquartered in Oslo, Norway.
Ultimovacs ASA Fundamentals Summary
| ULTI fundamental statistics | |
|---|---|
| Market cap | NOK 87.74m |
| Earnings (TTM) | -NOK 149.28m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.6x
P/E RatioIs ULTI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ULTI income statement (TTM) | |
|---|---|
| Revenue | NOK 0 |
| Cost of Revenue | NOK 0 |
| Gross Profit | NOK 0 |
| Other Expenses | NOK 149.28m |
| Earnings | -NOK 149.28m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 13, 2025
| Earnings per share (EPS) | -4.34 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ULTI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 05:22 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Ultimovacs ASA is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | ABG Sundal Collier |
| Geir Holom | DNB Markets |
| Christian Binder | Redeye |